

Matthias Preusser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8876202/publications.pdf>

Version: 2024-02-01

433
papers

25,544
citations

10986

71
h-index

9345

143
g-index

451
all docs

451
docs citations

451
times ranked

29395
citing authors

#	ARTICLE	IF	CITATIONS
1	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	35
2	Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. <i>European Journal of Surgical Oncology</i> , 2022, 48, 383-390.	1.0	3
3	Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. <i>Journal of Neurology</i> , 2022, 269, 1574-1590.	3.6	10
4	Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. <i>JAMA Oncology</i> , 2022, 8, 106.	7.1	53
5	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
6	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. <i>Neuro-Oncology Practice</i> , 2022, 9, 105-113.	1.6	10
7	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
8	Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. <i>European Journal of Cancer</i> , 2022, 162, 170-181.	2.8	18
9	MR Fingerprinting—A Radiogenomic Marker for Diffuse Gliomas. <i>Cancers</i> , 2022, 14, 723.	3.7	9
10	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	3.7	2
11	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
12	Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer. <i>Journal of Neurosurgery</i> , 2022, 137, 999-1005.	1.6	4
13	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events—a retrospective cohort study. <i>European Journal of Cancer</i> , 2022, 165, 184-194.	2.8	29
14	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	4.1	27
15	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.9	2
16	Toxicity management in severe and refractory cases—what we have learned. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 4-4.	0.5	0
17	The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
18	DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study. <i>Frontiers in Oncology</i> , 2022, 12, 811729.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	1.2	13
20	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy. <i>Pharmaceutics</i> , 2022, 14, 662.	4.5	3
21	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
22	Opportunities and challenges for the development of "core outcome sets" in neuro-oncology. <i>Neuro-Oncology</i> , 2022, 24, 1048-1055.	1.2	5
23	Enhanced expression of autophagy-related p62 without increased deposits of neurodegeneration-associated proteins in glioblastoma and surrounding tissue " An autopsy-based study. <i>Brain Pathology</i> , 2022, 32, e13058.	4.1	5
24	Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. <i>Cancer Cell</i> , 2022, 40, 444-446.	16.8	28
25	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	3.2	21
26	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. <i>Cancers</i> , 2022, 14, 2163.	3.7	3
27	Development of "Core Outcome Sets"™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. <i>BMJ Open</i> , 2022, 12, e057384.	1.9	7
28	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2055-2055.	1.6	0
29	Dermatitis linearis outbreak associated with <i>Paederus balcanicus</i> in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 511-515.	1.9	1
30	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2026-2026.	1.6	0
31	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
32	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , 2021, 137, 1669-1678.	1.4	123
33	Prevalence of pain and its association with symptoms of post-traumatic stress disorder, depression, anxiety and distress in 846 cancer patients: A cross sectional study. <i>Psycho-Oncology</i> , 2021, 30, 504-510.	2.3	26
34	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
35	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	27.6	826
36	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. <i>Clinical Nuclear Medicine</i> , 2021, 46, 16-20.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. <i>Molecular Cancer Research</i> , 2021, 19, 688-701.	3.4	22
38	High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, 532-541.	4.2	95
39	Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 1294-1300.	6.4	21
40	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	3.2	9
41	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2021, 13, 566.	3.7	21
42	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. <i>Cancers</i> , 2021, 13, 603.	3.7	12
43	Best of ASCO 2020. Memo - Magazine of European Medical Oncology, 2021, 14, 7-8.	0.5	0
44	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
45	BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI. <i>Neuro-Oncology Advances</i> , 2021, 3, i1-i1.	0.7	0
46	LAG-3 expression in the inflammatory microenvironment of glioma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 533-539.	2.9	22
47	Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. <i>ESMO Open</i> , 2021, 6, 100057.	4.5	13
48	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 1208-1209.	1.2	0
49	Reply to comment on "Analysis of the inflammatory tumor microenvironment in meningeal neoplasms", 2021, 40, 170.		0
50	Systemic and local inflammation characteristics in patients with cancer after lung transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, e14527-e14527.	1.6	0
51	Programmed death ligand-2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 287-293.	0.7	3
52	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	4.2	10
53	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	7.7	34
54	Androgen Receptor is Expressed in Breast Cancer Brain Metastases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 728-733.	1.2	1

#	ARTICLE	IF	CITATIONS
55	Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centre. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13623.	3.4	7
56	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. <i>Journal of Personalized Medicine</i> , 2021, 11, 624.	2.5	11
57	Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	3.7	8
58	SURF-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , 2021, 3, iii25-iii25.	0.7	0
59	SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 909-914.	1.9	2
60	Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106841.	1.4	0
61	Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?. <i>Cancers</i> , 2021, 13, 4632.	3.7	17
62	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	2.8	16
63	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1821-1834.	1.2	230
64	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	1.2	59
65	Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. <i>Cancers</i> , 2021, 13, 5050.	3.7	0
66	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
67	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 725903.	2.4	12
68	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 530-545.	1.4	2
69	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi127.	1.2	1
70	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. <i>Neuro-Oncology Advances</i> , 2021, 3, v35-v42.	0.7	2
71	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. <i>Neuro-Oncology</i> , 2021, 23, vi130-vi130.	1.2	0
72	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124.	1.2	0

#	ARTICLE	IF	CITATIONS
73	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 51-60.	6.4	98
74	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. <i>Clinical Neuroradiology</i> , 2020, 30, 599-605.	1.9	5
75	EORTC SPECTRA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	5.1	11
76	Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis. <i>Hormones and Cancer</i> , 2020, 11, 42-51.	4.9	10
77	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 422-430.	3.2	51
78	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. <i>NeuroImage: Clinical</i> , 2020, 28, 102433.	2.7	37
79	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-ONS-ANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1306-1319.	1.2	146
80	53. Genomic characterization of brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Cancer Genetics</i> , 2020, 244, 20-21.	0.4	1
81	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	4.1	27
82	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
83	Postoperative Magnetic Resonance Imaging After Surgery of Brain Metastases: Analysis of Extent of Resection and Potential Risk Factors for Incomplete Resection. <i>World Neurosurgery</i> , 2020, 143, e365-e373.	1.3	7
84	SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3554.	1.6	40
85	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors – Data from the Real-World Precision Medicine Platform MONDTI. <i>Journal of Personalized Medicine</i> , 2020, 10, 188.	2.5	7
86	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	2.8	14
87	Introducing a new ESMO Open article series: how I treat side effects of immunotherapy. <i>ESMO Open</i> , 2020, 4, e000552.	4.5	2
88	Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment. <i>ESMO Open</i> , 2020, 5, e000734.	4.5	0
89	SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000889.	4.5	39
90	Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. <i>Basic Research in Cardiology</i> , 2020, 115, 58.	5.9	28

#	ARTICLE	IF	CITATIONS
91	362O Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma. <i>Annals of Oncology</i> , 2020, 31, S397.	1.2	0
92	363O Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020. <i>Annals of Oncology</i> , 2020, 31, S397.	1.2	5
93	372MO Melanoma leptomeningeal metastases: A European multicenter cohort. <i>Annals of Oncology</i> , 2020, 31, S400-S401.	1.2	0
94	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. <i>Cancers</i> , 2020, 12, 2493.	3.7	14
95	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. <i>Cancers</i> , 2020, 12, 3775.	3.7	9
96	Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 450-452.	0.5	1
97	1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI. <i>Annals of Oncology</i> , 2020, 31, S1100.	1.2	0
98	1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors. <i>Annals of Oncology</i> , 2020, 31, S1051-S1052.	1.2	0
99	1877P Fatigue changes according to systemic therapy type in patients with advanced solid cancer. <i>Annals of Oncology</i> , 2020, 31, S1069.	1.2	0
100	1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria. <i>Annals of Oncology</i> , 2020, 31, S1000.	1.2	0
101	1462P Prognostic impact of clinical and laboratory nutritional markers in resectable gastroesophageal cancer. <i>Annals of Oncology</i> , 2020, 31, S916.	1.2	0
102	1487P Prognostic impact of thyroid hormone status in resectable gastroesophageal cancer. <i>Annals of Oncology</i> , 2020, 31, S924.	1.2	0
103	p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction. <i>Cancers</i> , 2020, 12, 3205.	3.7	8
104	Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1272.	2.4	56
105	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	2.9	25
106	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. <i>Pathology and Oncology Research</i> , 2020, 26, 2225-2235.	1.9	15
107	Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. <i>BMC Cancer</i> , 2020, 20, 410.	2.6	14
108	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39

#	ARTICLE	IF	CITATIONS
109	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
110	A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 895.	4.8	18
111	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177
112	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	2.8	10
113	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
114	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.7	14
115	Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3313-3322.	2.5	4
116	Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study. <i>Cancer Imaging</i> , 2020, 20, 16.	2.8	8
117	Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 965-975.	1.1	12
118	Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 779-786.	2.0	5
119	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. <i>Cancers</i> , 2020, 12, 301.	3.7	7
120	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
121	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. <i>ESMO Open</i> , 2020, 5, e000623.	4.5	4
122	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
123	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
124	Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2553-2553.	1.6	4
125	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. <i>Journal of Neurosurgery</i> , 2020, 133, 1032-1043.	1.6	19
126	Current Treatment Strategies in Breast Cancer Brain Metastases. , 2020, , 267-279.		0

#	ARTICLE	IF	CITATIONS
127	DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2020, 38, e18527-e18527.	1.6	1
128	Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases.. Journal of Clinical Oncology, 2020, 38, 2528-2528.	1.6	0
129	Abstract 4729: Identifying genomic drivers of lung adenocarcinoma brain metastases. , 2020, , .		0
130	Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors. , 2020, , .		0
131	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	4.5	4
132	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. Anticancer Research, 2020, 40, 6229-6236.	1.1	1
133	Analysis of the inflammatory tumor microenvironment in meningeal neoplasms. , 2020, 39, 256-262.		8
134	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. Neuro-Oncology, 2020, 22, ii129-ii129.	1.2	1
135	CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM. Neuro-Oncology, 2020, 22, ii54-ii54.	1.2	0
136	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro-Oncology, 2019, 21, 234-241.	1.2	16
137	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2019, 21, 26-36.	1.2	114
138	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology, 2019, 21, 1587-1594.	1.2	56
139	Âcase report of pseudo-progression after pembrolizumab in metastatic gastric cancer and aÂreview of immunotherapy in gastroesophageal tumors. Memo - Magazine of European Medical Oncology, 2019, 12, 51-59.	0.5	0
140	How we treat glioblastoma. ESMO Open, 2019, 4, e000520.	4.5	62
141	Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases. Annals of Oncology, 2019, 30, v148.	1.2	0
142	Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases. Annals of Oncology, 2019, 30, v152.	1.2	0
143	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. Neuro-Oncology Advances, 2019, 1, i33-i33.	0.7	0
144	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	7.7	386

#	ARTICLE	IF	CITATIONS
145	Screening for post-traumatic stress disorders in 1017 cancer patients and correlation with anxiety, depression, and distress. <i>Psycho-Oncology</i> , 2019, 28, 2382-2388.	2.3	25
146	OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients. <i>Neuro-Oncology</i> , 2019, 21, iii5-iii5.	1.2	1
147	A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis. <i>Annals of Oncology</i> , 2019, 30, iv67.	1.2	0
148	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
149	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. <i>Journal of Neuro-Oncology</i> , 2019, 145, 85-95.	2.9	13
150	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	21.4	315
151	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	4.5	38
152	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
153	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 967-976.	1.8	8
154	Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?. <i>Nature Reviews Neurology</i> , 2019, 15, 314-315.	10.1	13
155	High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T. <i>NeuroImage</i> , 2019, 191, 587-595.	4.2	33
156	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019, 4, e000507.	4.5	79
157	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
158	How we treat patients with brain tumour during the COVID-19 pandemic. <i>ESMO Open</i> , 2019, 4, e000789.	4.5	16
159	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open" Cancer Horizons Series. <i>ESMO Open</i> , 2019, 4, e000501.	4.5	6
160	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019, 21, vi17-vi17.	1.2	23
161	ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?. <i>Neuro-Oncology Advances</i> , 2019, 1, ii16-ii16.	0.7	0
162	LS2 METASTATIC BRAIN TUMORS / MENINGIOMAS: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES. <i>Neuro-Oncology Advances</i> , 2019, 1, ii2-ii3.	0.7	0

#	ARTICLE	IF	CITATIONS
163	P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer. <i>Neuro-Oncology</i> , 2019, 21, iii91-iii91.	1.2	0
164	Applied Precision Cancer Medicine in Neuro-Oncology. <i>Scientific Reports</i> , 2019, 9, 20139.	3.3	8
165	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , 2019, 11, 2020.	3.7	13
166	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	1.2	1
167	EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe. <i>Annals of Oncology</i> , 2019, 30, vii34-vii35.	1.2	0
168	EANOâ€œEURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	10.7	56
169	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. <i>Radiotherapy and Oncology</i> , 2019, 130, 139-148.	0.6	11
170	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 2737-2744.	7.0	34
171	PET imaging in patients with brain metastasisâ€œreport of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	1.2	139
172	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Openâ€œCancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	4.5	8
173	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. <i>EJNMMI Research</i> , 2019, 9, 110.	2.5	2
174	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007.	1.6	13
175	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
176	Correlation of systemic and local inflammation with survival prognosis in glioma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2052-2052.	1.6	0
177	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1435226.	4.6	36
178	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	7.4	194
179	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	2.8	17
180	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 135-144.	4.4	14

#	ARTICLE	IF	CITATIONS
181	Anti-angiogenic therapies in brain metastases. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 14-17.	0.5	26
182	Role of the blood-brain barrier in metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 57-66.	1.8	22
183	Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. <i>ESMO Open</i> , 2018, 3, e000262.	4.5	69
184	Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis. <i>Cancer Biology and Therapy</i> , 2018, 19, 169-174.	3.4	14
185	Advances in meningioma genetics: novel therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2018, 14, 106-115.	10.1	148
186	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.8	2
187	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
188	Visual and semiquantitative ¹¹ C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. <i>Neuro-Oncology</i> , 2018, 20, 411-419.	1.2	22
189	Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas. <i>Journal of Neurosurgery</i> , 2018, 129, 341-353.	1.6	35
190	Glioma Survival Prediction with Combined Analysis of In Vivo ¹¹ C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 892-899.	5.0	94
191	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , 2018, 20, vi59-vi59.	1.2	0
192	MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. <i>Neuro-Oncology</i> , 2018, 20, vi148-vi149.	1.2	0
193	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi155-vi155.	1.2	0
194	The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. <i>Oncotarget</i> , 2018, 9, 6968-6976.	1.8	31
195	High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. <i>PLoS ONE</i> , 2018, 13, e0207849.	2.5	63
196	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
197	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
198	Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin. <i>Cancer Discovery</i> , 2018, 8, 1316-1331.	9.4	123

#	ARTICLE	IF	CITATIONS
199	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	4.5	35
200	New developments in brain metastases. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878550.	3.5	25
201	MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas. <i>Journal of Cancer</i> , 2018, 9, 460-468.	2.5	9
202	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	30.7	359
203	Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 173-178.	2.9	62
204	PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome. <i>Histopathology</i> , 2018, 73, 573-584.	2.9	68
205	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , 2018, 129, 1104-1105.	1.6	2
206	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
207	5-ALA-induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. <i>Neurosurgical Focus</i> , 2018, 44, E7.	2.3	46
208	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. <i>European Radiology</i> , 2017, 27, 1556-1567.	4.5	26
209	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases – development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017, 19, now290.	1.2	26
210	Advances in brain tumour classification and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 71-72.	10.1	13
211	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , 2017, 129, 1831-1839.	1.4	164
212	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	1.2	381
213	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	1.5	24
214	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	10.1	125
215	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	10.7	816
216	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	1.2	213

#	ARTICLE	IF	CITATIONS
217	PET imaging in patients with meningioma—report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017, 19, 1576-1587.	1.2	157
218	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	1.8	28
219	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.5	8
220	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , 2017, 18, 682-694.	10.7	586
221	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. <i>European Radiology</i> , 2017, 27, 3167-3173.	4.5	80
222	External validation of the NUn score for predicting anastomotic leakage after oesophageal resection. <i>Scientific Reports</i> , 2017, 7, 9725.	3.3	9
223	CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology. <i>ESMO Open</i> , 2017, 2, e000194.	4.5	3
224	Evidence-based management of adult patients with diffuse glioma — Authors' reply. <i>Lancet Oncology</i> , 2017, 18, e430-e431.	10.7	5
225	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	4.5	4
226	Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. <i>Neuro-Oncology</i> , 2017, 19, 1280-1282.	1.2	3
227	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	530
228	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
229	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	2.8	34
230	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3562-3562.	1.6	1
231	Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520.	1.6	188
232	Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. , 2017, 36, 56-59.		19
233	Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2007-2007.	1.6	0
234	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2076-2076.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Meningioma research – status quo and quo vadis. <i>Chinese Clinical Oncology</i> , 2017, 6, S1-S1.	1.2	0
236	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	3.8	65
237	KINFix – A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens. , 2016, 35, 3-12.		12
238	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	4.5	11
239	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. <i>ESMO Open</i> , 2016, 1, e000024.	4.5	152
240	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 370-377.	2.8	25
241	Dura mater is a potential source of Aβ ² seeds. <i>Acta Neuropathologica</i> , 2016, 131, 911-923.	7.7	85
242	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology</i> , The, 2016, 17, e383-e391.	10.7	627
243	Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 727-739.	3.3	65
244	Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. <i>ESMO Open</i> , 2016, 1, e000056.	4.5	11
245	Evaluation of Dose-Staged Gamma Knife Radiosurgical Treatment Method for High-Risk Brain Metastases. <i>World Neurosurgery</i> , 2016, 94, 352-359.	1.3	15
246	In search of a target: PD-1 and PD-L1 profiling across glioma types. <i>Neuro-Oncology</i> , 2016, 18, 1331-1332.	1.2	18
247	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	2.9	107
248	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	4.5	17
249	Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 326-334.	1.2	14
250	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 70-75.	0.5	0
251	Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. <i>European Journal of Radiology</i> , 2016, 85, 540-545.	2.6	24
252	Case-Based Review: meningioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 120-134.	1.6	6

#	ARTICLE	IF	CITATIONS
253	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710.	4.1	103
254	BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 7-14.	4.1	16
255	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmunology</i> , 2016, 5, e1057388.	4.6	239
256	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	1.2	53
257	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. <i>Tumor Biology</i> , 2016, 37, 1173-1182.	1.8	39
258	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2072-2072.	1.6	1
259	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8563-8563.	1.6	1
260	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2079-TPS2079.	1.6	41
261	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e116-e122.	3.8	28
262	Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types. , 2016, 35, 89-92.		5
263	The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 519.	1.6	165
264	NephroCheck data compared to serum creatinine in various clinical settings. <i>BMC Nephrology</i> , 2015, 16, 206.	1.8	33
265	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <sc>cM</sc>et as a negative prognostic factor. <i>Histopathology</i> , 2015, 67, 799-805.	2.9	10
266	Prognostic role of tumour-infiltrating inflammatory cells in brain tumours. <i>Current Opinion in Neurology</i> , 2015, 28, 647-658.	3.6	33
267	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
268	Biology and Clinical Management Challenges in Meningioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e106-e115.	3.8	26
269	Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. <i>Anti-Cancer Drugs</i> , 2015, 26, 579-581.	1.4	6
270	New frontiers in neurooncology. <i>Current Opinion in Neurology</i> , 2015, 28, 626-627.	3.6	0

#	ARTICLE	IF	CITATIONS
271	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	3.0	24
272	Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, e41-55.	3.2	49
273	Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. <i>Neuro-Oncology</i> , 2015, 17, 588-595.	1.2	79
274	A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?. <i>Annals of Hematology</i> , 2015, 94, 345-346.	1.8	3
275	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1803-1811.	2.8	36
276	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	10.7	340
277	Antiangiogenic Treatment of Meningiomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 359.	1.8	5
278	microRNA-21 Expression is Elevated in Esophageal Adenocarcinoma After Neoadjuvant Chemotherapy. <i>Cancer Investigation</i> , 2015, 33, 246-250.	1.3	9
279	Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. <i>Biomarkers in Medicine</i> , 2015, 9, 327-335.	1.4	18
280	Haematopoietic stem cell transplantation for treatment of primary <i>CNS</i> lymphoma: single-centre experience and literature review. <i>European Journal of Haematology</i> , 2015, 95, 75-82.	2.2	10
281	A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. <i>Endoscopy International Open</i> , 2015, 03, E19-E28.	1.8	8
282	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98.	27.8	787
283	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	10.1	307
284	The future of targeted therapies for brain metastases. <i>Future Oncology</i> , 2015, 11, 2315-2327.	2.4	6
285	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	3.3	103
286	Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma. <i>Oncology</i> , 2015, 88, 173-179.	1.9	12
287	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. <i>Histopathology</i> , 2015, 66, 289-299.	2.9	99
288	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485

#	ARTICLE	IF	CITATIONS
289	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. Journal of Clinical Oncology, 2015, 33, e13026-e13026.	1.6	3
290	Correlation of plasma PD-L1 detectability with age in glioma patients.. Journal of Clinical Oncology, 2015, 33, e13039-e13039.	1.6	1
291	Brain metastasis research: a late awakening. Chinese Clinical Oncology, 2015, 4, 17.	1.2	5
292	The inflammatory microenvironment in brain metastases: potential treatment target?. Chinese Clinical Oncology, 2015, 4, 21.	1.2	51
293	Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. , 2015, 34, 250-257.		42
294	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. Journal of Clinical Oncology, 2015, 33, e13034-e13034.	1.6	0
295	Prognostic impact of breast cancer (BC) subtype in elderly patients.. Journal of Clinical Oncology, 2015, 33, e20536-e20536.	1.6	0
296	Trabectedin for Recurrent Grade II or III Meningioma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group. Neuro-Oncology Practice, 2015, 5, 44-44.	1.6	0
297	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care, 2014, 9, 6-6.	1.4	8
298	Downregulation of CIC Does Not Associate with Overexpression of ETV1 or MAP Kinase Pathway Activation in Gastrointestinal Stromal Tumors. Cancer Investigation, 2014, 32, 363-367.	1.3	2
299	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-Oncology, 2014, 16, 92-102.	1.2	57
300	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	7.7	54
301	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Archives of Dermatological Research, 2014, 306, 873-884.	1.9	11
302	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. SpringerPlus, 2014, 3, 111.	1.2	21
303	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	1.4	10
304	BRAF alterations in brain tumours. Current Opinion in Neurology, 2014, 27, 689-696.	3.6	34
305	Breast cancer brain metastases responding to primary systemic therapy with T-DM1. Journal of Neuro-Oncology, 2014, 116, 205-206.	2.9	61
306	Non-invasive assessment of intratumoral vascularity using arterial spin labeling: A comparison to susceptibility-weighted imaging for the differentiation of primary cerebral lymphoma and glioblastoma. European Journal of Radiology, 2014, 83, 806-810.	2.6	30

#	ARTICLE	IF	CITATIONS
307	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 771-778.	2.3	22
308	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89.	2.0	63
309	<i>BRAF</i> Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <i>CD34</i> Expression. <i>Brain Pathology</i> , 2014, 24, 221-229.	4.1	72
310	A step towards clinical blood biomarkers of glioblastoma. <i>Nature Reviews Neurology</i> , 2014, 10, 681-682.	10.1	14
311	ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. <i>Apmis</i> , 2014, 122, 867-872.	2.0	6
312	Amplification and overexpression of <i>CMET</i> is a common event in brain metastases of non-small cell lung cancer. <i>Histopathology</i> , 2014, 65, 684-692.	2.9	25
313	α 23, α 25 and α 26 integrins in brain metastases of lung cancer. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 841-851.	3.3	51
314	microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 679-692.	3.3	36
315	<i>ROS1</i> translocations and amplifications in lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 425-426.	2.9	15
316	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014, 23, 637-643.	2.2	56
317	Overexpression of <i>CMET</i> is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1354-1360.	2.8	28
318	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. <i>Breast Care</i> , 2014, 9, 134-134.	1.4	25
319	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	1.6	1
320	PD1 and PD-L1 expression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011.	1.6	4
321	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2012-2012.	1.6	1
322	T-DM1 in HER2-positive breast cancer brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 650-650.	1.6	1
323	A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. , 2014, 33, 50-60.		14
324	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, 33, 42-49.		100

#	ARTICLE	IF	CITATIONS
325	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45
326	Outcome evaluation in glioblastoma patients older than 65 years: Importance of individual assessment of treatment tolerance. , 2014, 33, 399-406.		7
327	Molecular biology of high-grade gliomas: what should the clinician know?. Chinese Journal of Cancer, 2014, 33, 4-7.	4.9	24
328	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).. Journal of Clinical Oncology, 2014, 32, 9055-9055.	1.6	1
329	QOL and neurocognitive functions in patients with GBM.. Journal of Clinical Oncology, 2014, 32, 2062-2062.	1.6	0
330	High plasma-GFAP levels in metastatic myxopapillary ependymoma. Journal of Neuro-Oncology, 2013, 113, 359-363.	2.9	8
331	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	2.9	14
332	The caregiversâ€™ perspective on the end-of-life phase of glioblastoma patients. Journal of Neuro-Oncology, 2013, 112, 403-411.	2.9	72
333	Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 2013, 112, 173-178.	2.9	59
334	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	7.7	177
335	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	1.2	191
336	AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762.	7.7	88
337	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Research and Treatment, 2013, 139, 13-22.	2.5	114
338	Optimal Management of Brain Metastases from Breast Cancer. CNS Drugs, 2013, 27, 121-134.	5.9	27
339	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	2.4	48
340	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thrombosis Research, 2013, 131, 162-165.	1.7	53
341	Primary systemic treatment of breast-cancer brain metastases. Lancet Oncology, The, 2013, 14, 8-9.	10.7	1
342	Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma – molecular testing procedures under scrutiny. , 2013, 32, 82-83.		4

#	ARTICLE	IF	CITATIONS
343	Circulating biomarkers of CNS tumors: an update. <i>Biomarkers in Medicine</i> , 2013, 7, 267-285.	1.4	16
344	Characterization of the inflammatory response to solid cancer metastases in the human brain. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 69-81.	3.3	81
345	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 357-368.	3.3	66
346	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 278-283.	2.0	59
347	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). <i>Neuro-Oncology</i> , 2013, 15, 112-121.	1.2	31
348	No Evidence for BRAF-V600E Mutations in Gastroesophageal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 426-430.	1.2	12
349	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 159-164.	1.2	27
350	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 351-353.	1.2	7
351	High-grade meningiomas. <i>Current Opinion in Neurology</i> , 2013, 26, 708-715.	3.6	14
352	Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1079-1083.	1.0	1
353	Frequent overexpression of ErbB " receptor family members in brain metastases of non-small cell lung cancer patients. <i>Apmis</i> , 2013, 121, 1144-1152.	2.0	15
354	Biology in prevention and treatment of brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1339-1348.	2.4	9
355	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	3.7	289
356	Antiangiogenic treatment approaches in breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 397-406.	0.2	0
357	NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi. <i>PLoS ONE</i> , 2013, 8, e69639.	2.5	63
358	Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2059-2059.	1.6	1
359	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. <i>PLoS ONE</i> , 2013, 8, e55464.	2.5	38
360	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. <i>PLoS ONE</i> , 2013, 8, e76988.	2.5	138

#	ARTICLE	IF	CITATIONS
361	External granular cell layer bobbling: a distinct histomorphological feature of the developing human cerebellum. , 2013, 32, 42-50.		4
362	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25
363	Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. Anticancer Research, 2013, 33, 1065-71.	1.1	15
364	CSF and laboratory analysis (tumor markers). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 143-148.	1.8	6
365	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. Oncologist, 2012, 17, e13-e17.	3.7	7
366	Brain metastasis. Current Opinion in Neurology, 2012, 25, 786-794.	3.6	20
367	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 844-850.	3.7	177
368	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 2012, 120, e28-e34.	1.4	199
369	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	1.3	19
370	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Journal of Neuro-Oncology, 2012, 109, 323-330.	2.9	20
371	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. Journal of Neuro-Oncology, 2012, 109, 331-339.	2.9	43
372	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. Translational Oncology, 2012, 5, 56-IN4.	3.7	71
373	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	1.3	60
374	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer, 2012, 48, 3439-3447.	2.8	37
375	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?. , 2012, 31, 405-408.		19
376	Clinically useful biomarkers in neurooncology. Memo - Magazine of European Medical Oncology, 2012, 5, 201-204.	0.5	1
377	Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer, 2012, 118, 5038-5049.	4.1	57
378	Bilateral retinal detachment in reactive arthritis: coincidence or association?. Wiener Klinische Wochenschrift, 2012, 124, 202-203.	1.9	2

#	ARTICLE	IF	CITATIONS
379	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. <i>Neurosurgical Review</i> , 2012, 35, 381-391.	2.4	86
380	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012, 60, 885-894.	2.9	44
381	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. <i>Magnetic Resonance Imaging</i> , 2012, 30, 139-147.	1.8	39
382	Pilot study on sex hormone levels and fertility in women with malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 387-394.	2.9	10
383	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233.	7.7	204
384	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	7.7	163
385	Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. , 2012, 31, 352-360.		49
386	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
387	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
388	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	1.6	0
389	Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2071-2071.	1.6	0
390	Blood alterations preceding clinical manifestation of glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2024-2024.	1.6	0
391	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the <i>IDH1-R132H</i> Mutation in Diffuse Glioma Biopsy Specimens. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 715-723.	1.7	98
392	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. <i>European Journal of Clinical Investigation</i> , 2011, 41, 539-545.	3.4	2
393	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. <i>Acta Neuropathologica</i> , 2011, 122, 11-19.	7.7	445
394	Current concepts and management of glioblastoma. <i>Annals of Neurology</i> , 2011, 70, 9-21.	5.3	380
395	Myxopapillary Ependymoma With Pleuropulmonary Metastases and High Plasma Glial Fibrillary Acidic Protein Levels. <i>Journal of Clinical Oncology</i> , 2011, 29, e756-e757.	1.6	14
396	IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, 30, 217-230.		55

#	ARTICLE	IF	CITATIONS
397	Neurocognitive training in patients with high-grade glioma: a pilot study. <i>Journal of Neuro-Oncology</i> , 2010, 97, 109-115.	2.9	78
398	Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well-Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. <i>Brain Pathology</i> , 2010, 20, 1010-1020.	4.1	22
399	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. <i>Pathology</i> , 2010, 42, 547-552.	0.6	42
400	Elevated blood markers 1 year before manifestation of malignant glioma. <i>Neuro-Oncology</i> , 2010, 12, 1004-1008.	1.2	16
401	Frequent MGMT (O6-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. <i>Radiology and Oncology</i> , 2010, 44, 113-20.	1.7	11
402	Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. <i>Cancer Biology and Therapy</i> , 2010, 9, 919-927.	3.4	7
403	mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. <i>Cancer Letters</i> , 2010, 296, 249-256.	7.2	40
404	Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. <i>Journal of Neurosurgery</i> , 2009, 111, 563-571.	1.6	34
405	O ⁶ -methylguanine DNA methyltransferase immunorexpression in nonfunctioning pituitary adenomas. <i>Cancer</i> , 2009, 115, 1070-1080.	4.1	48
406	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. <i>Journal of Neuro-Oncology</i> , 2009, 95, 401-411.	2.9	157
407	MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. <i>Histology and Histopathology</i> , 2009, 24, 511-8.	0.7	37
408	Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review. <i>Journal of Neuro-Oncology</i> , 2008, 90, 301-308.	2.9	56
409	Nigral burden of α -synuclein correlates with striatal dopamine deficit. <i>Movement Disorders</i> , 2008, 23, 1608-1612.	3.9	53
410	Anti-O ⁶ -Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. <i>Brain Pathology</i> , 2008, 18, 520-532.	4.1	189
411	Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. <i>Cancer Biology and Therapy</i> , 2008, 7, 1377-1385.	3.4	67
412	Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth <i>In vivo</i> . <i>Cancer Research</i> , 2007, 67, 11244-11253.	0.9	282
413	Angiocentric Glioma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1709-1718.	3.7	110
414	Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism. <i>Neuropathology</i> , 2007, 27, 453-456.	1.2	25

#	ARTICLE	IF	CITATIONS
415	Papillary glioneuronal tumor. <i>Neuropathology</i> , 2007, 27, 468-473.	1.2	33
416	OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms. <i>Histopathology</i> , 2007, 50, 365-370.	2.9	44
417	Secretagogin expression in tumours of the human brain and its coverings. <i>Apmis</i> , 2007, 115, 319-326.	2.0	7
418	TPPP/p25 in brain tumours: expression in non-neoplastic oligodendrocytes but not in oligodendroglioma cells. <i>Acta Neuropathologica</i> , 2007, 113, 213-215.	7.7	28
419	Autopsy at 2 months after death: Brain is satisfactorily preserved for neuropathology. <i>Forensic Science International</i> , 2007, 168, 177-182.	2.2	10
420	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 740-757.	1.7	95
421	Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. <i>Journal of NeuroVirology</i> , 2006, 12, 322-327.	2.1	121
422	Malignant glioma: <i>Neuropathology and Neurobiology</i> . <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 332-337.	1.1	46
423	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 46-55.	1.0	22
424	Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors. <i>Cancer</i> , 2006, 107, 162-170.	4.1	57
425	Imaging ex vivo healthy and pathological human brain tissue with ultra-high-resolution optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2005, 10, 011006.	2.6	82
426	Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: Implications for differential diagnosis. <i>Neuropathology</i> , 2005, 25, 241-246.	1.2	23
427	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. <i>Acta Neuropathologica</i> , 2005, 109, 211-216.	7.7	34
428	No prognostic impact of survivin expression in glioblastoma. <i>Acta Neuropathologica</i> , 2005, 109, 534-538.	7.7	26
429	Survivin Expression in Intracranial Ependymomas and Its Correlation With Tumor Cell Proliferation and Patient Outcome. <i>American Journal of Clinical Pathology</i> , 2005, 124, 543-549.	0.7	32
430	Visualization of Central European Tick-Borne Encephalitis Infection in Fatal Human Cases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 506-512.	1.7	164
431	Positive troponin T without cardiac involvement in inclusion body myositis. <i>Human Pathology</i> , 2005, 36, 917-921.	2.0	14
432	Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2004, 10, 6567-6571.	7.0	12

#	ARTICLE	IF	CITATIONS
433	Rosette-forming glioneuronal tumor of the fourth ventricle. Acta Neuropathologica, 2003, 106, 506-508.	7.7	63